ARZ.TO - Aralez Pharmaceuticals Inc.

Toronto - Toronto Delayed Price. Currency in CAD

Aralez Pharmaceuticals Inc.

7100 West Credit Avenue
Suite 101
Mississauga, ON L5N 0E4

SectorBasic Materials
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Adrian AdamsCEO & Director6.49MN/A1951
Mr. Andrew I. KovenPres & Chief Bus. Officer5.02MN/A1958
Mr. Mark A. GlickmanChief Commercial Officer1.09MN/A1966
Dr. James Patrick Tursi M.D.Chief Medical Officer1.12MN/A1965
Mr. Michael KasetaInterim CFO & Corp. ControllerN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain, and other specialty areas. It offers Yosprala for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events; Toprol-XL, a cardioselective beta-blocker indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia; Zontivity for the reduction of thrombotic cardiovascular events in patients; Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Fiorinal and Fiorinal C for the relief of tension type headaches; and Soriatane for the treatment of severe psoriasis and other disorders of keratinization. It also markets Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome; Proferrin, an iron supplement; and Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria. In addition, it commercializes Yosprala for the secondary prevention of cardiovascular disease in patients at risk for gastric ulcers. Further, its out-licensed products include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. The company was incorporated in 2015 and is headquartered in Mississauga, Canada.

Corporate Governance

Aralez Pharmaceuticals Inc.’s ISS Governance QualityScore as of March 1, 2018 is 4. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 4; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.